

Advances in Precision Combination Therapy

According to NCI, combination therapy is a type of therapy that combines more than one method of treatment. During the 12-month period covered in this report, FDA granted approvals to combinations of molecularly targeted therapeutics and immunotherapeutics to treat multiple types of cancer. Some of these approvals are listed below:



A combination of an **immunotherapeutic**, pembrolizumab (Keytruda), and a **molecularly targeted therapeutic**, bevacizumab (Avastin), approved in October 2021, to treat **certain patients with cervical cancer**.



A combination of **two immunotherapeutics**, relatlimab and nivolumab (Opdivo) [collectively called Opdivo], approved in March 2022, to treat **certain patients with melanoma**.



A combination of **two molecularly targeted therapeutics**, dabrafenib (Tafinlar) and trametinib (Mekinist), approved in June 2022, to treat **any patient with solid tumor carrying the BRAF V600E mutation**—with the exception of colorectal cancer.